| Cytokine |
Erythromycin N (95% CI) |
Placebo N (95% CI) |
P value |
|
Entry |
End |
Entry |
End |
|
| Serum |
| IL-1β |
3.3 (1.1-9.7) |
4.0 (2.3-7.0) |
4.1 (2.1-8.0) |
5.3 (2.1-13.3) |
0.31 |
| IL-6 |
6.9 (3.0-15.9) |
6.1 (3.0-12.5) |
18.4 (4.9-69.2) |
14.9 (4.6-47.8) |
0.31 |
| IL-8 |
18.9 (9.0-39.6) |
18.1 (7.4-44.2) |
24.2 (7.0-83.7) |
39.4 (12.9-119.8) |
0.26 |
| IL-10 |
3.9 (3.0-5.2) |
3.9 (2.5-6.1) |
4.8 (3.3-6.9) |
4.3 (3.0-6.0) |
0.51 |
| IP-10 |
4667.9 (2620.9-8613.5) |
3636.9 (2420.0-5465.8) |
2734.6 (2341.7-5956.0) |
3235.4 (2311.7-4528.3) |
0.24 |
| TNF-α* |
101.9 (-70.3-274.1) |
78.2 (-63.5-219.8) |
55.0 (-27.2-137.2) |
51.7 (3.8-99.7) |
0.74 |
| TNF-R1 |
111.8 (94.7-132.0) |
106.9 (92.5-123.6) |
119.5 (103.8-137.5) |
115.4 (100.8-132.1) |
0.95 |
| Sputum |
| IL-1β |
544.8 (198.0-1499.1) |
575.3 (177.1-1869.1) |
870.3 (366.8-2064.9) |
823.2 (434.5-1559.6) |
0.99 |
| IL-6 |
5.6 (2.5-12.6) |
2.9 (1.4-6.2) |
5.6 (2.4-13.1) |
4.6 (92.2-9.9) |
0.39 |
| IL-8 |
932.7 (341.1-2550.2) |
268.4 (81.0-888.9) |
1476.6 (537.5-4056.6) |
808.3 (274.7-2378.3) |
0.99 |
| IL-10 |
0.6 (0.5-0.9) |
0.6 (0.4-1.0) |
0.8 (0.4-1.33) |
0.7 (0.5-0.9) |
0.93 |
| IP-10 |
16.7 (4.1-68.5) |
7.8 (5.9-10.5) |
9.1 (6.9-11.9) |
11.2 (6.3-19.7) |
0.32 |
| TNF-α* |
15.0 (8.2-21.8) |
10.5 (5.7-19.4) |
17.0 (9.9-24.2) |
10.9 (6.2-19.0) |
0.97 |
| Elastase |
17.6 (13.2-23.4) |
18.9 (13.0-66.6) |
17.9 (13.1-24.6) |
20.3 (16.5-25.0) |
0.92 |
All mean reported as geometric means unless indicated; *Arithmetic means reported; sTREM: Soluble triggering receptor expressed on myeloid cells; IL- Interleukin:
TNF-α: Tumour necrosis factor alpha, IP-10: Interferon gamma induced protein -10; Units of all the cytokines in picograms per millimetre except elastase in nanograms
per litre. ANCOVA test used to obtain p-values for mean change from post treatment to mean change pre-treatment. |
